摘要:
A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water and a solvent are added to the mixture to form an organic phase comprising the ABDNAZ and an aqueous phase comprising the salt of DNAZ. The organic phase and the aqueous phase are separated to produce an ABDNAZ/solvent solution comprising the ABDNAZ and the aqueous phase comprising the salt of DNAZ. A nonsolvent is added to the ABDNAZ/solvent solution to produce an ABDNAZ/solvent/nonsolvent mixture. The ABDNAZ is subsequently recovered. A composition comprising ABDNAZ is also disclosed.
摘要:
A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water and a solvent are added to the mixture to form an organic phase comprising the ABDNAZ and an aqueous phase comprising the salt of DNAZ. The organic phase and the aqueous phase are separated to produce an ABDNAZ/solvent solution comprising the ABDNAZ and the aqueous phase comprising the salt of DNAZ. A nonsolvent is added to the ABDNAZ/solvent solution to produce an ABDNAZ/solvent/nonsolvent mixture. The ABDNAZ is subsequently recovered. A composition comprising ABDNAZ is also disclosed.
摘要:
The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
摘要:
The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
摘要:
The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
摘要:
Nitramines are one of the more expensive and often the more plentiful ingredients found in energetic materials, such as solid rocket motor propellants, explosives, and pyrotechnics. By treating aluminized energetic material with an aqueous nitric acid solution containing not more than 55% by weight aqueous nitric acid at a weight ratio of aqueous nitric acid to energetic material of about 4:1 to about 6:1, most constituents of conventional aluminized energetic materials are digested into solution, with the exception of nitramines, which remain substantially insoluble in the aqueous nitric acid and can be recovered without requiring recrystallization of the nitramines. A mineral acid other than nitric acid, preferably hydrochloric acid, is added to increase the rate of aluminum digestion. Treatment of the energetic material can be performed without volatile organic solvents, thus obviating ecological, cost, and safety concerns raised by the use of volatile organic solvents.
摘要:
A process of degrading nitramines by mixing the nitramine with an aqueous dispersion of metal powders and by heating the mixture is disclosed. HMX and RDX are typical nitramines which are degraded according to the present invention. Metal powders which have been successfully used include aluminum and zinc. The weight ratio of nitramine to metal powder is less than about 17:1. The aqueous mixture of nitramine and metal powder is preferably heated to a temperature greater than about 50.degree. C. and up to the boiling point of the mixture. Best results have been obtained when an aqueous base is used in connection with the metal powder. Aqueous ammonia and dilute hydroxide salt solutions are currently preferred aqueous base solutions.
摘要:
The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
摘要:
2,2-dinitro-1,3-propanediol-diformate is a novel low sensitivity, energetic plasticizer that is useful in explosive and propellant compositions. 2,2-dinitro-1,3-propanediol-diformate can be made by reacting 2,2-dinitro-1,3-propane diol with acetic formic anhydride in the presence of pyridine and at least one solvent.
摘要:
Glycerol is nitrated with at least one nitrating source in a solvent to form a nitrated glycerol solution containing dinitroglycerin. The nitrated glycerol solution is treated with at least one cyclizing agent to convert the dinitroglycerin into glycidyl nitrate, which is polymerized into poly(glycidyl nitrate) (PGN). Distillation or other vaporization techniques are not required to remove nitroglycerin from the glycidyl nitrate prior to polymerization of the glycidyl nitrate. Rather, the nitroglycerin can be carried along with the dinitroglycerin during polymerization. As a consequence, the glycidyl nitrate is not exposed to elevated temperatures sufficient to cause accidental explosion or deflagration of the nitrate ester. Still more preferably, the glycidyl nitrate is not heated above room temperature at any time prior to polymerization. Moreover, given the high energy performance of nitroglycerin, the nitroglycerin can optionally be retained with the PGN, i.e., not washed out, for subsequent processing and end use.